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Introductory Chapter: Recent 
Progress in Lung Cancer 




The remarkable advances in lung cancer management that we have witnessed 
in the past two decades did not arise in a vacuum. Surgeons, radiation oncologists, 
medical oncologists, pulmonologists, palliative care specialists, radiologists, pathol-
ogists, laboratory scientists, and patients have long collaborated to make the vision 
of improved cure rates, survival, and quality-of-life a reality.
2. Surgery
Minimally invasive surgery (MIS) has altered the landscape of thoracic surgery. 
Thoracotomies had been standard-of-care for lung cancer resections until the 
advent of video-assisted thoracoscopic surgery in the mid-1990s. While initially 
utilized primarily for patients with favorable anatomy and good pulmonary func-
tion, this has been increasingly adopted for use in more frail patients with more 
technically challenging anatomy [1]. Robotic-assisted thoracoscopic surgery was 
approved in the early-2000s with the help of even more sophisticated technology 
that imitated the manual dexterity of an open procedure.
With both approaches, there were initial concerns that there would be higher rates 
of complications as well as margin-positive resections that could translate into more 
intensive adjuvant regimens or poorer survival outcomes. Both techniques have sub-
stantial learning curves, but surgeons and centers gradually accumulated experience 
and increased the proportion of patients who underwent surgeries with a minimally 
invasive approach. Over a relatively short period of time, adoption of MIS has led to 
improved perioperative outcomes like pain, complications, length of hospital stay, 
and in-hospital costs without compromising oncologic outcomes [2, 3]. Not only has 
MIS allowed surgical patients to regain independence sooner than they would have 
otherwise, but also patients who may have not previously considered surgery due to 
the risk of morbidity might now be candidates for this potentially curative modality.
3. Radiotherapy and other ablative therapies
Nonsurgical local approaches have also expanded in scope due to developments 
in technology. Radiotherapy can now be administered with exceptional accuracy 
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and precision despite physiologic lung motion. This is largely due to improvements 
in image-guidance, 4-dimensional motion management, and beam modulation 
approaches that allow for higher biologically effective doses to the target, less scatter 
doses to normal organs, and more convenient treatment schedules.
Due to these advances, more ablative doses were made possible in the form of 
stereotactic body radiotherapy (SBRT), also known as stereotactic ablative body 
radiotherapy. Since its development in the mid-2000s, SBRT has been proven to 
be a valid alternative to surgical resection in early-stage disease, showing local 
control in the 90–98% range at 3–5 years with acceptable toxicity [4, 5]. SBRT has 
also been increasingly utilized in oligometastatic and oligoprogressive disease, with 
survival benefits demonstrated when used as consolidative therapy after systemic 
therapy [6, 7].
For inoperable locoregionally advanced non-small cell lung cancer, fractionated 
radiotherapy has been traditionally combined with chemotherapy with curative 
intent. With improved knowledge on appropriate radiotherapy dosing and the 
advent of consolidative immunotherapy, we can achieve better outcomes than we 
have ever seen before [8, 9]. Furthermore, image-guided ablative therapies like 
radiofrequency ablation, microwave ablation, and cryoablation have a wide range 
of potential indications. They can be particularly effective in situations that are not 
amenable to surgical or radiotherapeutic interventions due to safety concerns.
4. Systemic therapy
For more advanced disease, precision medicine has greatly expanded in its 
ability to address specific mutations and biomarkers with customized combinations 
of chemotherapy, targeted therapy, and immunotherapy. Drugs can now specifi-
cally target mutations like EGFR and ALK, effectively controlling even the most 
widespread metastases. Outcomes have continued to improve with refinements in 
successive generations of these agents [10, 11]. In addition, immunotherapy has 
been successfully used as monotherapy for patients with PD-L1 expressing tumors 
[12], or added to chemotherapy for patients with high, low, and no PD-L1 expres-
sion [13]. This has led to standard treatment regimens for most patients with stage 
IV non-small cell lung cancer. These combinations have also extended to extensive-
stage small cell lung cancer, with the addition of concurrent and maintenance 
immunotherapy representing the first major pharmacologic advance in the upfront 
treatment of this disease in several decades [14, 15].
Even for tumors that develop resistance to initial therapies, novel blood-based 
and tissue-based diagnostic testing can help clinicians formulate a truly personal-
ized approach to oncologic management, leading to the possibility of long-term 
survival that was unimaginable even a decade ago. Combining these systemic 
therapies with local therapies in the oligometastatic and oligoprogressive setting has 
led to unique regimens that have dramatically altered disease trajectories.
5. Palliative care
Palliative management of bone metastases has improved due to enhanced 
patient selection algorithms and surgical stabilization techniques by orthopedic 
surgeons and neurosurgeons, in addition to the judicious use of radiotherapy. Brain 
metastasis management has also evolved through increased utilization of upfront 
stereotactic radiosurgery [16] rather than whole-brain radiotherapy, mitigat-
ing potential cognitive effects without a survival detriment [17]. Furthermore, 
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integration of early palliative care for patients with advanced lung cancers has also 
contributed not only to improved quality-of-life, but also to survival [18].
6. Future directions and conclusions
Moving forward, utilization of cutting-edge technologies like circulating 
tumor biomarkers, machine learning, gas plasma, and nanotechnology may offer 
exciting new opportunities in screening, diagnosis, and therapy. While these may 
be in earlier stages of development than more standard modalities, they represent 
promising avenues for research and clinical application.
If the inspirational innovations discussed in this chapter are any indication, the 
future of personalized care for patients with lung cancer is exciting.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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